Presence and amount of gut bacteria can predict how fast pancreatic cancer cells grow

(Natural News) Pancreatic ductal adenocarcinoma, or PDA, is the most common and by far the most lethal form of pancreatic cancer. Pancreapedia reports that it is extremely aggressive, and for most patients their only hope of survival hinges on the total surgical removal of the tumor. Unfortunately, such tumors cannot be removed in upwards of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news

Related Links:

ConclusionsExpression of pER- β constitutes an independent prognostic marker for PDAC and is correlated with poor prognosis. These data may help in identifying novel drug targets in PDAC and patients who could benefit from additional therapeutic regimens, including selective estrogen receptor modulators.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAn elevated preoperative NLR was an important prognosticator for early TNM stage PDAC. The NLR, which is calculated using inexpensive and readily available biomarkers, could be a novel tool for predicting long-term survival in patients, especially those with early stage PDAC.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionsCAFs are highly chemoresistant. Direct cell–cell contact and high levels of IL-6 correlate with a high chemoresistance.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
In conclusion, NE may enhance the malignant biological behaviors of PDAC via activating the Notch‑1 pathway. PMID: 30226612 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Wang D, Wang R, Huang A, Fang Z, Wang K, He M, Xia JT, Li W Abstract Macrophage migration inhibitory factor (MIF) is a pro‑inflammatory cytokine that serves important roles in cancer. MIF overexpression is frequently observed in numerous human cancer types, including pancreatic carcinoma. However, the prognostic value and function of MIF in pancreatic ductal adenocarcinoma (PDAC) have not been fully elucidated. In the present study, upregulation of MIF expression in PDAC tissue compared with adjacent normal tissue was observed. Furthermore, MIF overexpression was identified to be significantly associate...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling. Biochem Biophys Res Commun. 2018 Sep 19;: Authors: Yang D, Tang Y, Fu H, Xu J, Hu Z, Zhang Y, Cai Q Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignancies with very poor prognosis due to its broad resistance to chemotherapy. Our previous study showed that integrin β1 expression is upregulated in PDAC and confers gemcitabine resistance in PDAC cells via the signaling pathway including Cdc42 and AKT activation. But the accurate signal transduc...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Although current guidelines recommend multimodal therapy for all patients with pancreatic ductal adenocarcinoma, it is unclear the extent to which clinical stage I patients are accurately staged and how this may affect management.
Source: Surgery - Category: Surgery Authors: Source Type: research
Conclusions: Loss of FOXO1 protein is identified as an early event during PDAC development and may be independent of the top 4 mutated cancer genes. Because of its strong expression in normal ductal cells, immunohistochemical detection of FOXO1 can function as a valuable test to establish the diagnosis of transformation and malignancy in pancreatic tissues.Pathobiology
Source: Pathobiology - Category: Pathology Source Type: research
In this study, we aimed to test if zirconium-89 transferrin ([89Zr]Zr-Tf) could measure changes in MYC depending on KRAS status of PDAC, and assess target engagement of anti-MYC and anti-ERK targeted therapies. RESULTS: Mice bearing iKras*p53* tumors showed significantly higher (P
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Condition:   Pancreatic Adenocarcinoma Intervention:   Sponsor:   Ospedale San Raffaele Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Pancreas | Pancreatic Cancer